New combo therapy for advanced lung cancer tested in Real-World study
NCT ID NCT07247227
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a combination of the immunotherapy drug Sugemalimab and standard chemotherapy as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that has spread. The goal is to see how well this combo works in real-world clinics, not just in controlled trials. About 150 participants will receive the treatment, and researchers will track how long they live without the cancer getting worse, overall survival, and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sugemalimab (an immunotherapy drug) plus platinum-based chemotherapy
What this could lead to
If successful, this could show that Sugemalimab plus chemo works well in everyday clinical practice for advanced lung cancer, potentially improving survival and treatment options.
What could go wrong
This is an early, single-arm study without a comparison group, so results may not be definitive. Side effects from immunotherapy and chemo can be serious, and the real-world setting may introduce variability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
cancer hospital， Chinese Academy of medical sciences and Peking union medical college
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••